- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2015
- Public Summary Document (PSD) November 2015 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2015 PBAC Meeting - Word
Bevacizumab – November 2015
Bevacizumab: solution for I.V. use, 100 mg in 4 mL and 400 mg in 16 mL, Avastin®
Last updated
18 March 2016